Lumet 80 Tablet contains a fixed-dose combination of Artemether 80mg and Lumefantrine 480mg, indicated for the treatment of uncomplicated Plasmodium falciparum malaria. Artemether, a potent artemisinin derivative, acts rapidly against the asexual erythrocytic stages of malaria parasites by generating reactive oxygen species that damage parasite proteins and membranes. Lumefantrine, a longer-acting antimalarial agent, inhibits heme polymerization within the parasite, thereby exerting sustained antimalarial activity and preventing recrudescence. The synergistic combination ensures rapid parasite clearance and reduces the risk of resistance development. Lumet 80 Tablet is administered orally, typically as a six-dose regimen over three days, with doses taken at 0, 8, 24, 36, 48, and 60 hours. It is essential to complete the full course to achieve optimal therapeutic outcomes. The medication is contraindicated in patients with known hypersensitivity to artemether, lumefantrine, or related compounds. Caution is advised in individuals with cardiac conduction abnormalities due to potential QT interval prolongation. Common adverse effects include headache, dizziness, anorexia, and gastrointestinal disturbances. Lumet 80 Tablet should be used under medical supervision, with attention to proper dosing and monitoring for adverse reactions to ensure safe and effective malaria treatment.